Mutant KRAS at the Heart of Tumor Immune Evasion

Febe van Maldegem; Julian Downward

doi:10.1016/j.immuni.2019.12.013

Mutant KRAS at the Heart of Tumor Immune Evasion

Febe van Maldegem^*, Julian Downward

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.

Original language	English
Pages (from-to)	14-16
Number of pages	3
Journal	Immunity
Volume	52
Issue number	1
DOIs	https://doi.org/10.1016/j.immuni.2019.12.013
Publication status	Published - 14 Jan 2020
Externally published	Yes

Access to Document

10.1016/j.immuni.2019.12.013

Cite this

@article{10a8c1ad24f64346a5b6c9b76e10f934,

title = "Mutant KRAS at the Heart of Tumor Immune Evasion",

abstract = "In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.",

author = "{van Maldegem}, Febe and Julian Downward",

note = "Funding Information: J.D. has acted as a consultant for AstraZeneca, Bayer, Novartis, Vividion, and TheRas. The authors have no other financial interests to declare related to this work. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = jan,

day = "14",

doi = "10.1016/j.immuni.2019.12.013",

language = "English",

volume = "52",

pages = "14--16",

journal = "Immunity",

issn = "1074-7613",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Mutant KRAS at the Heart of Tumor Immune Evasion

AU - van Maldegem, Febe

AU - Downward, Julian

N1 - Funding Information: J.D. has acted as a consultant for AstraZeneca, Bayer, Novartis, Vividion, and TheRas. The authors have no other financial interests to declare related to this work. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2020/1/14

Y1 - 2020/1/14

N2 - In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.

AB - In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=85077574685&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2019.12.013

DO - 10.1016/j.immuni.2019.12.013

M3 - Article

C2 - 31951548

AN - SCOPUS:85077574685

SN - 1074-7613

VL - 52

SP - 14

EP - 16

JO - Immunity

JF - Immunity

IS - 1

ER -

Mutant KRAS at the Heart of Tumor Immune Evasion

Abstract

Access to Document

Other files and links

Cite this